1)17名患者中的11名(64.7%)在6个月时实现了总体肾脏反应,即尿蛋白与肌酐比值(UPCR)减少50%或更多;2)17名患者中有6名(35.2%)达到完全肾脏反应,包括在6个月时UPCR为0.5或更少;3...查看全文
格隆汇6月28日丨Kezar Life Sciences(KZR.US)飙升81.66%,报10.5美元。该公司今日公布,其肾病药物zetomipzomib在治疗活动性狼疮性肾炎的第二阶段临床试验呈现出积极数据,第二阶段topline数据显示,参加试验的21名患者中有17名达到治疗结束,而17名患者中... 网页链接
$Kezar Life Sciences, Inc.(KZR)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2018-07-02 AccNo: 0000929638-18-000617 Size: 132 KB 网页链接
$Kezar Life Sciences, Inc.(KZR)$ CT ORDER - Confidential treatment order Filed: 2018-06-21 AccNo: 9999999997-18-006519 Size: 10 KB 网页链接
$Kezar Life Sciences, Inc.(KZR)$ EFFECT - Notice of Effectiveness Filed: 2018-06-20 AccNo: 9999999995-18-001559 Size: 1 KB 网页链接
$Kezar Life Sciences, Inc.(KZR)$ CERT - Filed: 2018-06-19 AccNo: 0001354457-18-000208 Size: 80 KB 网页链接
$Kezar Life Sciences, Inc.(KZR)$ 8-K - Current report Filed: 2018-06-26 AccNo: 0001193125-18-204228 Size: 214 KBItem 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Kezar Life Sciences, Inc.(KZR)$ S-8 - Securities to be offered to employees in employee benefit plans Filed: 2018-06-21 AccNo: 0001193125-18-198518 Size: 260 KB 网页链接
$Kezar Life Sciences, Inc.(KZR)$ 424B4 - Prospectus [Rule 424(b)(4)] Filed: 2018-06-21 AccNo: 0001193125-18-198510 Size: 3 MB 网页链接
$Kezar Life Sciences, Inc.(KZR)$ S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)] Filed: 2018-06-20 AccNo: 0001193125-18-198362 Size: 54 KB 网页链接
$Kezar Life Sciences, Inc.(KZR)$ 8-A12B - Registration of securities [Section 12(b)] Filed: 2018-06-19 AccNo: 0001193125-18-196541 Size: 13 KB 网页链接
$Kezar Life Sciences, Inc.(KZR)$ S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933 Filed: 2018-06-19 AccNo: 0001193125-18-196220 Size: 3 MB 网页链接